basic transcription factor 3 like 4Genealiases: []
Q-omics provides the consensus-scored BTF3L4 profile across patient tissues and cancer cell-line models. BTF3L4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BTF3L4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, BTF3L4 protein abundance shows 21,220 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, HNSC, and PDAC as cancer lineages where BTF3L4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3L4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3L4 survival associations across molecular data types. BTF3L4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3L4 RNA expression–survival associations across cancer types. High BTF3L4 expression shows unfavorable associations in LIHC, KIRP, ACC, SARC and KICH, but favorable associations in LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BTF3L4 RNA expression.
This table summarizes BTF3L4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BTF3L4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3L4 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, BLCA, KIRC and LUAD. The HNSC box plot shows higher BTF3L4 RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with BTF3L4 in patient tissues and cancer cell lines. In patient samples, BTF3L4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTF3L4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
